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Abstract 
 
Objectives: To evaluate the use of biological agents in treatment of psoriasis and to explore 
country-specific differences within 6 Central and Eastern European (CEE) countries, namely 
Bulgaria, Croatia, the Czech Republic, Hungary, Poland, and Romania. 
Methods: A literature overview on the epidemiology and disease burden of psoriasis in CEE 
was conducted. Numbers of patients treated with biologics were obtained from patient 
registries, ministries of health, national professional societies, and health insurance funds. 
Biological treatment rates were estimated by two different methods: (i) as a proportion of all 
psoriasis patients of a country (assuming a common prevalence of psoriasis 2%) and (ii) per 
100,000 population. Moreover, we provide a detailed comparison of reimbursement policies 
and guidelines regulating the treatment with biological drugs.  
Results: On average 0.25% of all psoriasis patients, or 5 psoriasis patients out of 100,000 
inhabitants are treated with biologics embedding a 14.6-fold difference between the six 
countries. Bulgaria, Croatia, and Poland are lagging behind the other three countries in use of 
biologics. The significant differences among countries cannot be explained by variations in 
prices of biologics or cost-effectiveness or budget impact of biologics. It seems that the time 
since reimbursement decision, the fewer number of reimbursed biologics, the more restrictive 
criteria to be eligible for reimbursed treatment in terms of baseline Psoriasis Area and 
Severity Index, Dermatology Life Quality Index scores, and the maximum duration of 
treatment allowed are responsible for the majority of the differences.  
Conclusions: Spread of biologics in certain CEE countries is not hindered by the high costs 
of biologics, rather by the unfavourable reimbursement policies and guidelines. Presumably 
decision makers and payers less recognise psoriasis as a severe condition that can be 
successfully treated in a cost-effective manner. 
 
Keywords: psoriasis, biological drugs, drug utilization, Central and Eastern Europe 
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Introduction 
 
Introduction of biological drugs implied the greatest advance in the management of moderate 
to severe psoriasis of the past decade. In 2004, etanercept was the first biological drug 
registered by the European Medicines Agency (EMA), followed by infliximab (2005), 
adalimumab (2007) and ustekinumab (2008) for the treatment of patients with moderate to 
severe plaque psoriasis who failed to respond to, or who have a contraindication to, or are 
intolerant to other systemic therapy including cyclosporine, methotrexate, or psoralen and 
ultraviolet-A light (PUVA).1,2 Additionally, in September 2013, biosimilar infliximab was 
approved by EMA in the same indications as the reference product.2  
 
Psoriasis is a life-long condition that significantly diminishes health related quality of life 
(HRQOL) and may have long-term effects on patients’ well-being.3-5 However, biological 
therapy can considerably improve clinical outcomes and HRQOL of patients.6-8 Alongside the 
beneficial clinical profile of biologics, high drug costs impose challenges for many countries 
in terms of reimbursement. An extensive study across 46 European countries in another 
chronic inflammatory disease (rheumatoid arthritis, RA) revealed that access to biologics is 
positively associated with countries’ welfare; therefore, patients in lower income European 
countries have less access to biological drugs.9 Two previous studies, focusing on use of 
biologics for inflammatory rheumatic conditions and inflammatory bowel diseases, reported 
considerable differences in biological treatment rates between countries in the Central and 
Eastern European (CEE) region.10,11 Nevertheless, no evidence is available from CEE in this 
area concerning psoriasis. Considering the differences in economic performance across CEE, 
one would expect more psoriasis patients treated with biologics in higher-income countries. 
Either it is unclear whether the high costs of biologics are per se responsible for the low 
treatment rate of certain countries, or do other factors underpin the differences. In the next 
years, a series of biosimilar drugs are expected to be registered which offer price advantage 
compared to the original drugs. Thus, the increasing penetration of biosimilars may 
substantially modify the entire biological drug market, especially in CEE. 
 
The purpose of this paper is, therefore, to provide an overview on the current use of biological 
drugs for the treatment of psoriasis patients in 6 CEE countries, namely Bulgaria, Croatia, the 
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Czech Republic, Hungary, Poland, and Romania. First, we summarise the available literature 
data on the epidemiology and disease burden of psoriasis in CEE. Secondly, we provide 
country-specific utilisation data on biologics in psoriasis in the six CEE countries and 
compare reimbursement policies and guidelines regulating the treatment with biological 
drugs. Third, we investigate and discuss the potential reasons for inter-country differences and 
set against other selected chronic systemic inflammatory diseases from CEE. 
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Methods 
 
Epidemiology and disease burden 
A Medline-based literature review on the epidemiology and disease burden of psoriasis in 
CEE was conducted until the 31st October 2014. In addition, authors provided data regarding 
ongoing studies and conference abstracts available on these topics from their own countries.  
 
Biological treatment rates 
Number of patients with biological treatment was obtained from different sources by country 
such as patient registries, health insurance databases, ministries of health, and national 
professional societies. Treatment rates were estimated by two different methods: (i) patients 
treated with biologics as a proportion of all psoriasis patients of a country and (ii) patients 
treated with biologics per 100,000 inhabitants. The latter method filters out potential bias due 
to the unknown country-specific epidemiology. Population data used were obtained from 
Eurostat Statistics Database.12 Correlation between health expenditure (retrieved from The 
World Bank Databank13) and the number of psoriasis patients on biological treatment was 
analysed for each country.  
 
Reimbursement guidelines and policies 
Data on reimbursement guidelines and policies were gathered through document analysis and 
pooling of country expertise. A common set of questions and issues, that pertains the 
regulation on use of original biologics and as well biosimilars, was sent out to experts in the 
six countries. Data were further validated and refined through consultation with other CEE 
Health Technology Assessment (HTA) experts and policy-makers, and through discussions 
among the authors. 
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Results 
 
Epidemiology 
We identified three studies that investigated the epidemiology of psoriasis in the CEE region, 
so far.14-16 Prevalence of psoriasis among adults was assessed only in Croatia. A nationwide 
study (year 1989) reported prevalence of adult psoriasis 1.55% and a study from Karlovac 
region (year 1991) observed a prevalence of 0.75%.14,15 In Romania (year 1999), prevalence 
of psoriasis was noted 0.25% among Romanian schoolchildren aged 6-12 years.16  
Nevertheless, up-to-date country-specific incidence and prevalence data including all age-
groups from the CEE countries are still lacking. Thus, we had to rely on estimations in our 
analyses. No evidence was found supporting that a difference in epidemiology of psoriasis 
within CEE exists; therefore, assuming a common prevalence of 2% for all the six countries 
(prevalence in Europe varies between 0.73% and 2.9%)17 we estimated that in 2013, more 
than 1.8 million people lived with psoriasis in the six countries (Table 1).  
 
Disease burden of psoriasis 
 
Of the four psoriasis cost-of-illness studies that have been carried out in CEE countries and 
presented in 5 publications (Table 2), only one study from Hungary has been published as a 
full-text paper in an English-language peer-reviewed journal, findings from other countries 
were merely published as conference abstracts.18-22 Although the four studies had similar 
aims, direct comparison of the results is hampered by the different inclusion criteria, unknown 
proportion of patients on biologics, and costing methods.  
 
 
Number of patients on biologics 
A total of 4,591 psoriasis patients are receiving biologics in more than 73 centres of the six 
selected countries which is estimated to be 0.25% of all psoriasis patients (Table 1). On 
average 5 psoriasis patients out of 100,000 inhabitants are treated with biologics embedding a 
1.1-14.6-fold difference between the six countries. Bulgaria, Croatia, and Poland are lagging 
behind the other three countries in use of biologics (Figure 1). 
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A moderate correlation between number of patients treated with biologics per 100,000 
inhabitants and countries’ total expenditure on health revealed (r=0.50, p=0.802); however, it 
was not significant due to the small number of countries involved. Remarkably, Romania 
treats on average 7.9 patients per 100,000 inhabitants despite its rather low per capita health 
expenditure ($420). By contrast, as a respect of the higher per capita health expenditure of the 
Czech Republic ($1,432), on average 11.2 patients per 100,000 population, receiving 
biologics seems few. 
 
 
Reimbursement of biologics 
 
Reimbursement of biological drugs for the treatment of psoriasis started the earliest in the 
Czech Republic (2005), Hungary (2006), and Romania (2010), while in Bulgaria, Croatia and 
Poland only in 2013-2014 (Table 3). Currently, biologics are reimbursed in all the six 
countries and are covered without co-payment for the patients. However, in Bulgaria the 
National Health Insurance Fund and the pharmaceutical companies share financing on 75/25 
(Table 3). In the six countries, all the four aforementioned original biologics are reimbursed, 
with the exception of infliximab in Poland and ustekinumab in Romania. 
In 2014, biosimilar infliximab drugs were begun to be marketed in Bulgaria, the Czech 
Republic, Hungary, and Romania, and are reimbursed at the same level as the original drug. 
Nevertheless, the introduction is lagging in Croatia, Poland, and Romania.  
 
Reimbursement guidelines 
The six countries apply similar clinical eligibility criteria for reimbursement regarding 
biological therapy based on the recommendations of the European-S3 Guidelines1,23-25 
Biologics are recommended in moderate to severe psoriasis patients who meet certain 
eligibility criteria expressed in Psoriasis Area and Severity Index (PASI), and/or Body 
Surface Area (BSA) and/or Dermatology Life Quality Index (DLQI) after being treated for at 
least 6 months with traditional systemic therapy or in case of these are not tolerated or 
contraindicated.1 However, in financial guidelines, severity scores required to be eligible for 
reimbursed treatment are different from those in professional guidelines.1,26 In Bulgaria 
(PASI>20 or BSA>20), Croatia (PASI>15 and/or BSA>15 and/or DLQI>15), and Poland 
(PASI>18, DLQI>10, and BSA>10) eligibility criteria are rather restrictive and only patients 
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with higher severity scores (and worse health status) are allowed to treat with biologics, 
whereas in the Czech Republic, Hungary and Romania, criteria are closer to those in the 
European-S3 Guidelines (Table 3).1 In all countries, but Poland, first assessment of treatment 
effect is required at week 12 after the initiation of the biological therapy.  
In most countries, maintenance therapy is allowed for patients who reach a response of ≥50% 
reduction in PASI, and in addition ≥5 points improvement in DLQI. Duration of treatment is 
unlimited, except for Poland, where adalimumab and ustekinumab can be applied up to 48 
weeks and etanercept up to 24 weeks, respectively.  
In all the six countries, switch between different biological substances (both original and 
biosimilar, where applicable) is allowed, if adverse events or inefficiency develop.  
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Discussion 
 
This paper concerned the use of biological therapy to treat psoriasis in six CEE countries. We 
found that on average 0.25% of all psoriasis patients, or 5 psoriasis patients out of 100,000 
population are treated with biologics in CEE. Proportion of patients treated within the six 
countries varied as follows: Bulgaria 0.06%, Croatia 0.19%, the Czech Republic 0.56%, 
Hungary 0.63%, Poland 0.04%, and Romania 0.39%. Similarly, in other chronic 
inflammatory conditions, great heterogeneity was noted between CEE countries varying 
between 1.3-10% in rheumatoid arthritis (RA), and 0.7-19.1% in Crohn’s disease (CD) (6 
countries were considered: Bulgaria, the Czech Republic, Hungary, Poland, Romania, and 
Slovakia).10,11  
 
Comparison with the PSONET countries 
Registry to follow up psoriasis patients treated with biologics has been established in Croatia, 
the Czech Republic, Hungary, and in Poland, so far. However, they are not incorporated in the 
greatest psoriasis registry network, the PSONET (http://www.psonet.eu) which is a 
collaborative network between independent disease registries for patients receiving 
conventional or biological systemic therapy for psoriasis.27,28 Currently, PSONET contains 
data on more than 20,000 patients from 10 Northern and Western European countries, 
Australia, and Israel.29,30 In Germany, between 2004-2007 according to an analysis of 
psoriasis patients’ data retrieved from the statutory health insurances joined to PSONET, 
biological therapy was given to approximately in 0.1% of all psoriasis patients.31 A few years 
later, in 2010, biological treatment rates in the PSONET countries were estimated as follows: 
Germany 0.25%, UK 0.2%, Denmark 0.2%, Italy <1%, and Sweden 1.6%.27 Treatment rates 
described in CEE and in the PSONET registries are not comparable due to the different years 
of data collection. However, the number of patients on biologics has presumably increased 
since 2010; therefore, we anticipate that a treatment gap between the Western European and 
CEE countries exists.  
 
Inter-country differences within CEE 
A 1.1 to 14.6-fold difference between the six countries in use of biologics was found; 
Bulgaria, Croatia, and Poland are lagging behind the Czech Republic, Hungary, and Romania 
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(Figure 1). Experts usually state that various factors may play important role in these 
differences such as epidemiology, total health expenditure per capita, prices of biologics, 
disease burden, cost-effectiveness of biologics, health care financing mechanisms, medical 
professionals’ lobbying power, local reimbursement policy, and guidelines.  
 
Even though there are no valid prevalence and incidence data available from CEE, we 
presume that inter-country variations in epidemiology cannot be per se responsible for such 
great differences. Neither the difference in prices of biologics explains the extent of 
heterogeneity observed in use (adalimumab €957-1,262, etanercept €975-1,164, infliximab 
€481-€609 (per dose national list prices).32 Total costs covered by health insurance are 
available only from Hungary that provide some evidences on budget impact of psoriasis.33 In 
2010, average annual per patient drug costs of biologicals for psoriasis amounted to €9,916, 
whereas budget impact of all psoriasis patients amounted to €6.8 million, respectively.33 We 
assume that biologics for psoriasis generate similar per patient outflow in the other six 
countries as well. 
 
Total health expenditure per capita of these 6 countries ($420-1,432) seems to partly explain a 
proportion of the differences in biologic use (Figure 1). Reimbursement policies and 
guidelines may also obstacle the widespread use of biologics in certain countries. In Bulgaria, 
Croatia, and Poland start of reimbursement was delayed 7-9 years compared to the Czech 
Republic and Hungary which commenced the reimbursement earliest among the six countries. 
We believe therefore that the time since reimbursement decision is one of the factors that 
highly influences the treatment rates.  
 
Besides, we found that use of biologics highly depends on eligibility criteria applied for 
reimbursement. The very high baseline PASI and DLQI scores required in Bulgaria, Croatia, 
and the somewhat lower in Poland largely explain the lower use observed in these countries 
(Table 3). Contrarily, countries with less restrictive criteria, such as Romania and the Czech 
Republic, demonstrate considerably higher treatment rates. However, despite the less 
favorable criteria applied in Hungary (i.e. PASI>15 and DLQI>10), it holds the highest 
treatment rate out of the six countries. In case of Poland, the limited duration of treatment 
reimbursed may also hamper use of biologics. Furthermore, the lack of reimbursement of 
infliximab in Poland and ustekinumab in Romania to treat psoriasis as well might contribute 
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to the lower biologic use of these countries. In addition, Croatia and Poland do not cover 
biosimilar infliximab, either.  
It appears therefore that use of biologics for psoriasis in certain CEE countries, such as 
Bulgaria, Croatia, and Poland, is not hindered by the high costs of biologics, rather by the 
unfavourable reimbursement policies and guidelines. And if so, these countries with their 
fairly unsuitable conditions for the penetration of biologics, will presumably not benefit as 
much from the lower-cost biosimilars either, as they could if less restrictive eligibility criteria 
are employed.  
 
Further challenges 
In most CEE countries, fairly similar HTA-based decision-making is applied in 
reimbursement that requires economic evaluations.34,35 Disease burden of psoriasis patients 
treated with biological therapy is unknown in CEE countries except for Hungary (Table 2).4,18 
Annual individual direct costs of Hungarian moderate to severe psoriasis patients receiving 
biologics are in line with findings from Northern and Western Europe (€13,505-18,457).36  
 
As for cost-utility analyses, the international literature suggest that biologics are cost-effective 
alternatives for the treatment of psoriasis in countries such as UK, Germany, Sweden, Italy, 
the US, and Canada (£30,000-42,000/quality-adjusted life years - QALY).37 In CEE, 
empirical country-specific data is only available from Poland; however, cost-effectiveness 
results are redacted in the publicly accessible documents.38 Nevertheless, Gulácsi et al. have 
estimated that cost-effectiveness of biologics used in dermatology, rheumatology, and 
gastroenterology in CEE, noticing very similar cost/QALY results in psoriasis, RA, and CD.34 
In psoriasis, multiples of per capita gross domestic product (GDP) per QALY of biologics 
vary between 4.13-4.79 in Bulgaria, 1.79-2.57 in the Czech Republic, 2.29-3.03 in Hungary, 
2.53-3.05 in Poland, and 3.29-3.86 in Romania.34 Thus, in many cases the estimated rate 
exceeds the threshold of 3 times per capita GDP/QALY applied in reimbursement decision 
making in the Czech Republic, Hungary, Poland and Romania.34,35,39 We propose local cost-
effectiveness analyses in CEE countries that might facilitate the changes in reimbursement 
guidelines to approximate the criteria laid down in the European-S3 Guidelines.1 
 
Patients with moderate to severe psoriasis associated with psoriatic arthritis represent a further 
challenge of biological therapy in psoriasis, since biologics may be effective for both the skin 
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and the joint condition. In randomised controlled trials (RCT) of biologics, the achieved 
average health gain measured by EQ-5D at week 12-54 were 0.12-0.21 in moderate to severe 
psoriasis and 0.24-0.28 in psoriasis associated with psoriatic arthritis.6,7,40-42 Hence, from the 
viewpoint of health economics, in this patient group, cost-effectiveness of biologics might 
exceed that reported in psoriasis or in psoriatic arthritis separately which might support the 
increasing use of biologics.22 
 
Limitations 
Possible limitation of this study is uncertainty of estimations due to lack of prevalence data 
from CEE. Patient numbers reported here do not include those patients who finance biologics 
for themselves, either those who receive the drugs within hospital budget, or under diagnosis-
related group-based (DRG) financing, or as a part of a compassionate programme of a 
pharmaceutical company. Nonetheless, experts state that the proportion of these patients 
could be considered marginal. In all countries but Hungary, patients on each substance 
include the switchers as well, and hence, the total number of patients is minimally 
overestimated. Also, comparison of country-specific reimbursement systems might be limited 
due to necessary simplifications. 
 
Conclusions 
To sum up, on average 0.25% of all psoriasis patients, or 5 psoriasis patients out of 100,000 
inhabitants are treated with biologics. Use of biological treatment in CEE might be limited 
compared to Western and Northern Europe. With respect to the number of patients treated 
with biologics out of 100,000 inhabitants, a 14.6-fold difference was noted across the six 
countries; Bulgaria, Croatia, and Poland are lagging behind the other three countries in 
treatment rates. The significant differences among countries cannot be explained by variations 
in prices, cost-effectiveness, or budget impact of biologics. It seems that the time since 
reimbursement decision, the fewer number of reimbursed biologics, the more restrictive 
criteria to be eligible for reimbursed treatment in terms of baseline PASI and DLQI, and the 
maximum duration of treatment allowed are the factors that are responsible for the majority of 
the differences. Based on the available data, we presume that decision makers and payers less 
recognise psoriasis as a severe condition that can be successfully treated in a cost-effective 
manner. Our findings call for further research, including the implementation of local registries 
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to follow-up patients, and disease burden and cost-effectiveness studies that may help to 
inform decision-makers about the true burden of psoriasis. 
Page 14 of 38Journal of European Academy of Dermatology Venereology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 
13 
 
References 
 
1 Pathirana D, Ormerod AD, Saiag P, Smith C, Spuls PI, Nast A et al. European S3-
guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol 
2009; 23 Suppl 2: 1-70. 
2 European Medicines Agency.  http://www.ema.europa.eu/ema/  Accessed: 08/09/2014 
3 de Korte J, Sprangers MA, Mombers FM, Bos JD. Quality of life in patients with 
psoriasis: a systematic literature review. J Investig Dermatol Symp Proc 2004; 9: 140-147. 
4 Heredi E, Rencz F, Balogh O, Gulacsi L, Herszenyi K, Hollo P et al. Exploring the 
relationship between EQ-5D, DLQI and PASI, and mapping EQ-5D utilities: a cross-sectional 
study in psoriasis from Hungary. Eur J Health Econ 2014; 15 Suppl 1: S111-119. 
5 Rencz F, Hollo P, Karpati S, Pentek M, Remenyik E, Szegedi A et al. Moderate to 
severe psoriasis patients' subjective future expectations regarding health-related quality of life 
and longevity. J Eur Acad Dermatol Venereol 2014 Dec 10. [Epub ahead of print]. 
6 Reich K, Segaert S, Van de Kerkhof P, Durian C, Boussuge MP, Paolozzi L et al. 
Once-weekly administration of etanercept 50 mg improves patient-reported outcomes in 
patients with moderate-to-severe plaque psoriasis. Dermatology 2009; 219: 239-249. 
7 Revicki D, Willian MK, Saurat JH, Papp KA, Ortonne JP, Sexton C et al. Impact of 
adalimumab treatment on health-related quality of life and other patient-reported outcomes: 
results from a 16-week randomized controlled trial in patients with moderate to severe plaque 
psoriasis. Br J Dermatol 2008; 158: 549-557. 
8 Shikiar R, Willian MK, Okun MM, Thompson CS, Revicki DA. The validity and 
responsiveness of three quality of life measures in the assessment of psoriasis patients: results 
of a phase II study. Health Qual Life Outcomes 2006; 4: 71. 
9 Putrik P, Ramiro S, Kvien TK, Sokka T, Pavlova M, Uhlig T et al. Inequities in access 
to biologic and synthetic DMARDs across 46 European countries. Ann Rheum Dis 2014; 73: 
198-206. 
10 Pentek M, Poor G, Wiland P, Olejarova M, Brzosko M, Codreanu C et al. Biological 
therapy in inflammatory rheumatic diseases: issues in Central and Eastern European 
countries. Eur J Health Econ 2014; 15 Suppl 1: S35-43. 
11 Rencz F, Péntek M, Bortlik M, Zagorowicz E, Hlavaty T, Liwczyński A et al. 
Biological therapy in inflammatory bowel diseases: Access in Central and Eastern Europe. 
World Journal of Gastroenterology 2015; 21. 
12 Eurostat Statistics Database, 2013. 
http://epp.eurostat.ec.europa.eu/portal/page/portal/statistics/search_database  Accessed: 
10/08/2014. 
13 World Bank Databank, 2012. http://databank.worldbank.org/data/home.aspx 
Accessed: 10/08/2014. 
14 Barisic-Drusko V, Paljan D, Kansky A, Vujasinovic S. Prevalence of psoriasis in 
Croatia. Acta Derm Venereol Suppl (Stockh) 1989; 146: 178-179. 
15 Del Toso-Depeder Z. Prevalence of psoriasis in the Karlovac region. Lijec Vjesn 1993; 
115: 21-27. 
16 Popescu R, Popescu CM, Williams HC, Forsea D. The prevalence of skin conditions 
in Romanian school children. Br J Dermatol 1999; 140: 891-896. 
17 Parisi R, Symmons DP, Griffiths CE, Ashcroft DM. Global epidemiology of psoriasis: 
a systematic review of incidence and prevalence. J Invest Dermatol 2013; 133: 377-385. 
Page 15 of 38 Journal of European Academy of Dermatology Venereology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 
14 
 
18 Balogh O, Brodszky V, Gulacsi L, Heredi E, Herszenyi K, Jokai H et al. Cost-of-
illness in patients with moderate to severe psoriasis: a cross-sectional survey in Hungarian 
dermatological centres. Eur J Health Econ 2014; 15 Suppl 1: S101-109. 
19 Klimes J, Dolezal T. Indirect costs of moderate to severe forms of psoriasis in Czech 
Republic: calculation based self reported questionnaire. Value Health 2010; 13: A468. 
20 Petrikova A, Klimes J, Dolezal T, Marinov L, G. P. Treatment of Patients with 
Moderate and Severe Psoriasis – Cost-of-Illness in the Czech Republic. Value Health 2011; 
14: A305–A306. 
21 Władysiuk M, Fedyna M, Bebrysz M, Mateusz H, Rutkowski J, Owczarek W et al. 
Indirect costs of rheumatoid arthritis, Crohn's disease and psoriasis in Poland. Health 
Technology Assessment International Conference 2014; June 2014: 60. 
http://www.htai2014.org/temp/20147448232/OR244.pdf   Accessed: 08/10/2014 
22 Rencz F, Brodszky V, Péntek M, Balogh O, Remenyik É, Szegedi A et al. Disease 
burden of psoriasis associated with psoriatic arthritis in Hungary. Orv Hetil 2014; 155: 1913–
1921. 
23 Arenberger P. Organizace biologické léčby v ČR. 1st conference of biological 
medicines 2010; November 12-13., 2010. http://www.prolekare.cz/odborny-event/organizace-
biologicke-lecby-v-cr-11   Accessed: 10/08/2014 
24 Országos Egészségbiztosítási Pénztár E, Orvosszakértői és Szakmai Ellenőrzési 
Főosztály. A plakkos psoriasis diagnosztikájának és kezelésének finanszírozási protokollja 
(eljárásrend). 2013.06.26.;  
http://site.oep.hu/steam/downloads/finprot_20131115/hatalyos/0626_a_plakkos_psoriasis_dia
gnosztikajanak_es_kezelesenek_finanszirozasi_protokollja.pdf  Accessed: 10/08/2014 
25 Kadurina M, Vassileva S, Gospodinov D, Dobrev H, Kazandjieva J, Mateev G et al. 
Guidelines for the Treatment of Psoriasis by Biological Products of Bulgarian Dermatological 
Society. 2013;  http://www.bg-derm.org/wp-content/uploads/2013/06/02-Guideline-for-
biologicals.pdf  Accessed: 10/08/2014 
26 Mrowietz U, Kragballe K, Reich K, Spuls P, Griffiths CE, Nast A et al. Definition of 
treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res 
2011; 303: 1-10. 
27 Ormerod AD, Augustin M, Baker C, Chosidow O, Cohen AD, Dam TN et al. 
Challenges for synthesising data in a network of registries for systemic psoriasis therapies. 
Dermatology 2012; 224: 236-243. 
28 Garcia-Doval I, Rustenbach SJ, Stern R, Dam TN, Cohen AD, Baker C et al. Systemic 
psoriasis therapy shows high between-country variation: a sign of unwarranted variation? 
Cross-sectional analysis of baseline data from the PSONET registries. Br J Dermatol 2013; 
169: 710-714. 
29 Lecluse LL, Naldi L, Stern RS, Spuls PI. National registries of systemic treatment for 
psoriasis and the European 'Psonet' initiative. Dermatology 2009; 218: 347-356. 
30 Naldi L. on behalf of the Psonet network. The Psonet Collaboration. 9th ENCePP 
Plenary Meeting 2012; 3 May 2012. 
http://www.encepp.eu/publications/documents/3.2_Psonet.pdf   Accessed: 10/08/2014 
31 Augustin M, Glaeske G, Schafer I, Rustenbach SJ, Hoer A, Radtke MA. Processes of 
psoriasis health care in Germany--long-term analysis of data from the statutory health 
insurances. J Dtsch Dermatol Ges 2012; 10: 648-655. 
32 Brodszky V, Baji P, Balogh O, Pentek M. Budget impact analysis of biosimilar 
infliximab (CT-P13) for the treatment of rheumatoid arthritis in six Central and Eastern 
European countries. Eur J Health Econ 2014; 15 Suppl 1: S65-71. 
33 Laki J, Monok G, Palosi M, Gajdacsi JZ. Economical aspect of biological therapy in 
inflammatory conditions in Hungary. Expert Opin Biol Ther 2013; 13: 327-337. 
Page 16 of 38Journal of European Academy of Dermatology Venereology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 
15 
 
34 Gulacsi L, Rencz F, Pentek M, Brodszky V, Lopert R, Hever NV et al. Transferability 
of results of cost utility analyses for biologicals in inflammatory conditions for Central and 
Eastern European countries. Eur J Health Econ 2014; 15 Suppl 1: S27-34. 
35 Gulacsi L, Pentek M. HTA in Central and Eastern European countries; the 2001: a 
space odyssey and efficiency gain. Eur J Health Econ 2014; 15: 675-680. 
36 Feldman SR, Burudpakdee C, Gala S, Nanavaty M, Mallya UG. The economic burden 
of psoriasis: a systematic literature review. Expert Rev Pharmacoecon Outcomes Res 2014; 
14: 685-705. 
37 Zhang W, Islam N, Ma C, Anis AH. Systematic Review of Cost-Effectiveness 
Analyses of Treatments for Psoriasis. Pharmacoeconomics 2014. 
38 Agencja Oceny Technologii Medycznych. Wydział do Spraw Systemów Ochrony 
Zdrowia. Wniosek o objęcie refundacją leku Stelara (ustekinumab), 45 mg,  w ramach 
programu lekowego: Leczenie cięzkiej postaci łuszczycy pospolitej z zastosowaniem 
ustekinumabu. Analiza weryfikacyjna 2012;  
http://www.aotm.gov.pl/bip/assets/files/zlecenia_mz/2012/044/AWA/044_AWA_DS_433_05
_Stelara_luszczyca_2012.08.13.pdf  Accessed: 12/12/2014 
39 Gulacsi L, Rotar AM, Niewada M, Loblova O, Rencz F, Petrova G et al. Health 
technology assessment in Poland, the Czech Republic, Hungary, Romania and Bulgaria. Eur J 
Health Econ 2014; 15 Suppl 1: S13-25. 
40 Gniadecki R, Robertson D, Molta CT, Freundlich B, Pedersen R, Li W et al. Self-
reported health outcomes in patients with psoriasis and psoriatic arthritis randomized to two 
etanercept regimens. J Eur Acad Dermatol Venereol 2012; 26: 1436-1443. 
41 Luger TA, Barker J, Lambert J, Yang S, Robertson D, Foehl J et al. Sustained 
improvement in joint pain and nail symptoms with etanercept therapy in patients with 
moderate-to-severe psoriasis. J Eur Acad Dermatol Venereol 2009; 23: 896-904. 
42 Shikiar R, Heffernan M, Langley RG, Willian MK, Okun MM, Revicki DA. 
Adalimumab treatment is associated with improvement in health-related quality of life in 
psoriasis: patient-reported outcomes from a phase II randomized controlled trial. J 
Dermatolog Treat 2007; 18: 25-31. 
 
 
Page 17 of 38 Journal of European Academy of Dermatology Venereology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 
16 
 
 
Table 1 Number of psoriasis patients treated with biologics annually in 6 CEE countries, 
2014 or latest  
Countries 
Estimated 
number 
of 
psoriasis 
patients 
Dermatology 
centres 
entitled to 
administer 
biologics adalimumab etanercept infliximab ustekinumab Total 
Estimated 
proportion 
of patients 
treated 
with 
biologics 
BGR 145,691 3 8 15 60** 2 85 0.06% 
CRO 85,243 5                      34 15 15 95 159 0.19% 
CZE 210,323 18 540 270 96 282 1,188 0.56% 
HUN 198,176 9 240 427 266 407 1,252* 0.63% 
POL 770,666 38 114 16 NR 204 334§ 0.04% 
ROM 400,401 §§ 584 623 366 NR 1,573 0.39% 
Total 1,810,500 >73 1,520 1,366 803 990 4,591 0.25% 
*Calculated by excluding the number of switchers. 
** All biosimilar infliximab. 
§ Patient numbers for Poland cover the period between May, 2013 and August, 2014. Of note, total number of 
patients receiving biologics might be slightly higher due to other sources of financing such as diagnosis-related 
groups (DRG)-based. 
§§ All dermatologists are allowed to prescribe biologics regardless of the centre.  
NR: not reimbursed.  
Population data (2013): Eurostat Statistics Database12 
Number of patients: patient registries, health insurance databases, ministries of health, national professional 
societies 
Prevalence of psoriasis: 2% (estimation). 
BGR: Bulgaria, CRO: Croatia, CZE: Czech Republic, HUN: Hungary, POL: Poland, ROM: Romania
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Table 2 Disease burden of psoriasis in six Central and Eastern European countries  
Author, year 
Publication 
type, language 
Country 
Year 
of 
costs 
Patients Method 
Perspective of 
costs 
calculation 
Type of 
costs 
reported 
Average yearly cost per 
patient (indirect costs 
%) 
Balogh et al., 
201418 * 
 
full-text, 
English 
 
Hungary 2012 
N=200, moderate to severe 
mean age 51 years 
BST: 51.5% 
questionnaire 
survey 
societal 
direct and 
indirect 
(both HCA 
and FCA) 
HCA:  
   NST €2,186 (58%) 
   TST €2,388 (40%) 
   BST €15,790 (9%) 
FCA:  
   NST €1,132 (18%) 
   TST: €1,973 (28%) 
   BST: €14,562 (1%)** 
Rencz et al., 
201422 * 
full-text, 
Hungarian 
Hungary 2012 
N=57, moderate to severe 
psoriasis with PsA 
mean age: 54 years 
BST: 47% 
questionnaire 
survey 
societal 
direct and 
indirect 
(HCA) 
NST €1,729 (61%) 
TST €1,799 (43%) 
BST €16,983 (17%)** 
 
Petrikova et 
al., 201120 
conference 
paper, English 
Czech 
Republic 
NR 
N=259, moderate to severe 
mean age 47 years 
BST: 0% 
questionnaire 
survey 
societal 
direct and 
indirect 
(FCA) 
with PsA €4,328 (31%)  
without PsA €3,737 
(23%) 
Klimes – 
Dolezal, 
201019 
conference 
paper, English 
Czech 
Republic 
2009 
N=179, moderate to severe 
mean age 45 years 
BST: NR 
questionnaire 
survey 
governmental 
indirect 
(FCA) 
absenteeism €214 
part-time €168 
fulltime disability €414 
Władysiuk et 
al., 201421 
conference 
paper, English 
Poland 2012 
N=460, severity: 6% remission, 
54% mild, 29% moderate, and 
12% of high activity disease 
age: 18-65 years,  
BST: NR 
questionnaire 
survey 
societal 
indirect 
(HCA) 
absenteeism €1,466 
presenteeism €4,111§ 
* same study, where the 57 patients with PsA is a subsample of the 200 patients analysed by Balogh et al.18; ** EUR 1 = HUF 285; § EUR 1 = USD 1.34; BST: biological 
systemic therapy, FCA: friction cost approach; HCA: human capital approach; NR: not reported; NST: not receiving systemic therapy (topical treatment or none), PsA: 
psoriatic arthritis; TST: traditional systemic therapy 
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Table 3 Biological and biosimilar therapy in psoriasis, reimbursement criteria and guidelines in 6 CEE countries 
 Bulgaria Croatia Czech Republic Hungary Poland Romania 
National/regional 
registry of psoriasis 
patients  
No 
Registry owned by 
National Referral 
Centre for psoriasis 
Biorep* - includes 
the majority of 
insured patients on 
biologics 
Insurance database 
for patients on 
biologics 
System of Monitoring 
Therapeutic Programs 
(SMPT) for patients on 
biologics 
No 
Reimbursement 100%§ 100% 100% 100% 100% 100% 
Date from first 
biological is 
reimbursed for the 
treatment of psoriasis 
March 1, 2014 Aug 10, 2014 2005 March 2006 January 1, 2013** June 2010 
Date from first 
biosimilar is 
reimbursed for the 
treatment of psoriasis 
March 1, 2014 Not reimbursed October, 2013 May 15, 2014 Not reimbursed*** April 1, 2014 
Clinical severity 
criteria for being 
eligible to start 
reimbursed biological 
therapy 
PASI >20 or BSA>20 
PASI >15 and /or 
BSA>15 
and/or DLQI>15  
PASI>10 and 
DLQI>10 
PASI>15 and 
DLQI>10 
PASI>18, DLQI>10, 
and BSA>10 §§ 
PASI ≥ 10 and 
DLQI≥10 
Assessment of 
effectiveness after the 
initiation 
at week 12 and every 
6 months afterwards 
at week 12 and at 
week 28 
at week 12 between week 12-16 
at week 4, and every 12 
weeks afterwards with 
some additional drug 
specific monitoring 
activities 
at week 12 and every 
6 month afterwards 
Criteria of eligibility 
for maintenance 
therapy 
PASI improvement 
≥75% or PASI 
improvement ≥50% 
and DLQI 
improvement ≥ 5 
points 
at week 12: PASI 
improvement ≥50% 
and DLQI 
improvement ≥ 5 
points  
at week 28: PASI 
improvement ≥75% 
or PASI 
improvement ≥50% 
and DLQI 
PASI improvement 
≥50% 
PASI improvement 
≥50% and DLQI 
improvement ≥ 5 
points 
PASI improvement 
≥50% and DLQI 
improvement ≥ 5 points 
PASI improvement 
≥50% and DLQI 
improvement ≥ 5 
points 
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improvement ≥ 5 
points 
Is the duration of 
biological treatment 
limited? 
No No No No 
Yes, adalimumab and 
ustekinumab 48 weeks, 
etanercept 24 weeks 
No 
Is switching between 
original biologics 
allowed? 
Yes, if inefficacy or 
side effects develop 
Yes, if inefficacy or 
side effects develop 
Yes, if inefficacy or 
side effects develop 
(but the patient have 
to meet inclusion 
criteria of starting a 
new biological)  
Yes, if inefficacy or 
side effects develop 
Yes, if inefficacy or 
side effects develop 
Yes, if inefficacy or 
side effects develop 
Is switching between 
biologics and 
biosimilars allowed? 
Not applicable due to 
original infliximab is 
not reimbursed 
Not applicable 
Yes (but the patient 
have to meet 
inclusion criteria of 
starting a new 
biological) 
Yes Yes*** Yes 
Are biosimilars 
allowed to use as a 
first choice biological 
treatment?  
Yes Not applicable Yes Yes Not applicable§§§ Yes 
BSA = body surface area; DRG = diagnosis-related group; DLQI = Dermatology Life Quality Index; PASI = Psoriasis Area and Severity Index 
* http://www.biorep.cz 
** DRG-based financing was started from April 6, 2011 and a Drug Program to finance biologics was established in January 1, 2013 with ustekinumab followed by 
adalimumab (July 1, 2013), and finally etanercept (November, 2014). 
*** Biosimilars are available under DRG-based financing only. 
§ 75% is paid by the National Health Insurance Fund and 25% by the pharmaceutical company 
§§ For DRG-based financing: PASI>10, DLQI>10, and BSA>10 
§§§ Yes, in DRG-based financing system 
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Figure 1 Total health expenditure per capita and number of psoriasis patients treated 
with biologics per 10
5
 inhabitants in 6 selected CEE countries 
 
Sizes of bubbles refer to the absolute number of patients treated with biologics in each country. 
Patient number: patient registries, health insurance databases, ministries of health, national 
professional societies (2014 or latest) 
Population data (2013): Eurostat Statistics Database12 
Total health expenditure per capita (2012): World Bank Databank13 
BGR: Bulgaria, CRO: Croatia, CZE: Czech Republic, HUN: Hungary, POL: Poland, ROM: Romania 
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